Safety Safety data from studies on aciclovir use in HSV infections would apply (1). Pharmacokinetics

Safety data from studies on aciclovir use in HSV infections would apply (1).

A study of 28 infants evaluated the pharmacokinetics of aciclovir in neonates with postmenstrual age (PMA) 25–41 weeks and 1–30 postnatal days. Aciclovir pharmacokinetics was described by a 1-compartment model and the study proposed dosing: 20 mg/kg 12 hourly in PMA < 30 weeks; 20 mg/kg 8 hourly in PMA 30 to < 36 weeks and 20 mg/kg 6 hourly in PMA 36–41 weeks.⁴ (LOE III-3) Another pharmacokinetic study of 16 neonates born at gestational ages of 27–40 weeks, postnatal age 1–56 days, described aciclovir pharmacokinetics as two-compartment and found a relationship between clearance and serum creatinine concentration. Dosing recommendations are given based on creatinine, with a “standard dose” being 10 mg/kg /dose 8 hourly for a neonate with normal renal function.³ (LOE III-3, GOR C).